Last reviewed · How we verify
TS-142
At a glance
| Generic name | TS-142 |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea. (PHASE1)
- A Phase I Study of TS-142 in Healthy Participants (Single Doses) (PHASE1)
- Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder (PHASE2)
- Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole) (PHASE1)
- Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects (PHASE2)
- A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment (PHASE1)
- Long-Term Study of TS-142 in Patients with Insomnia (PHASE3)
- A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-142 CI brief — competitive landscape report
- TS-142 updates RSS · CI watch RSS
- Taisho Pharmaceutical Co., Ltd. portfolio CI